Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
Running, not enrolling
Conditions studied: Hiv
In brief
Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acting Cabotegravir (CAB-LA) as the first long-acting medication for HIV prevention. This study will evaluate real world clinical outcomes of cisgender female patients who start CAB-LA for PrEP.
Key facts
- Study ID
- NCT06145854
- Run by
- Midway Specialty Care Center
- People needed
- 100
- Starts
- 2024-01-02
- Expected to finish
- 2027-03-31
- Last updated by the study team
- 2025-11-03
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Cisgender females, ages 18 years and older
- Negative HIV test at baseline
- Negative Pregnancy test at baseline
- Weigh at least 35 kilograms
- Already Prescribed CAB-LA (Apretude)
You may not qualify if…
- Transgender females or males
- Cisgender males
- Cisgender female who is actively breastfeeding
- Severe hepatotoxicity
- Evidence of Hepatitis B Infection
- History or presence of allergies to cabotegravir or its components
Where it is running
- Midway Specialty Care Center — Orlando, Florida, United States
- Midway Specialty Care Center — Temple Terrace, Florida, United States
- Midway Specialty Care Center — West Palm Beach, Florida, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.